Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States; however, HCC incidence and mortality are not equally distributed among racial/ethnic groups. Our aim was to characterize the direction and magnitude of racial/ethnic disparities in overall survival and early tumor detection among patients with HCC.We searched MEDLINE, EMBASE and Cochrane databases from inception through August 2020 for studies reporting HCC outcomes (early stage presentation and overall survival) by race and ethnicity. We calculated pooled hazard ratios (HRs) and odds ratios (ORs) for each racial/ethnic group (White, Black, Hispanic, Asian) using the DerSimonian and Laird method for a random-effects model.We identified 35 articles comprising 563,097 patients (53.0% White, 17.3% Black, 18.4% Hispanic, 5.0% Asian). Compared to Whites, Black patients had worse survival (pooled HR 1.08, 95%CI 1.05 - 1.12), whereas Hispanic (pooled HR 0.92, 95%CI 0.87 - 0.97) and Asian (pooled HR 0.81, 95%CI 0.73 - 0.88) patients had better survival. Among articles reporting tumor stage (n=20), Blacks had lower odds of early stage HCC compared to Whites (OR 0.66, 95%CI 0.54 - 0.78). Conversely, there was no difference in odds of early HCC detection for Asian (OR 1.01, 95%CI 0.97 - 1.05) or Hispanic patients (OR 0.87, 95%CI 0.74 - 1.01) compared to Whites. The most common limitation of studies was risk of residual confounding from socioeconomic status and liver dysfunction.There are significant racial and ethnic disparities in HCC prognosis in the United States, with Black patients having worse overall survival and Hispanic and Asian patients having better overall survival compared to White patients. Interventions are needed to reduce disparities in early HCC detection to improve HCC prognosis.